Download full document (pdf) - Ansell Healthcare Europe

More documents

Recommendations

Info

Hemorrhagic fever viruses Viral hemorrhagic fevers (VHFs) refer to a group of illnesses that are caused by several distinct families of viruses. Each disease causes a febrile syndrome characterized by hemorrhagic complications, but mortality rates, incubation periods and susceptibility to antiviral therapy vary depending on the etiologic agent. While some types of hemorrhagic fever can cause relatively mild illnesses, many of these viruses cause severe, life-threatening disease. These organisms pose a biological threat due to their potential to cause severe morbidity and because transmission can occur from 13, 14 person to person. The viruses that are considered the most dangerous if weaponized include the filoviruses (Ebola and Marburg), New World aarenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia), flaviviruses (Omsk hemorrhagic fever, Kyasanur Forest disease), and bunyaviruses (Rift Valley fever). Diagnosis Patient presenting with a fever greater than 101 degrees Fahrenheit with at least two accompanying symptoms would be suspect. Notification of the local health department is necessary. For decisions regarding obtaining and processing diagnostic specimens, contact local, state, and regional laboratory authorities or CDC. Treatment Patients receive supportive therapy because there is no established cure for VHF’s. Ribavirin, an anti-viral drug, has been effective in treating some individuals with Lassa fever. Treatment with convalescent-phase plasma has been used with success in some patients. Post Exposure Prophylaxis There is no post exposure prophylaxis currently available for VHF. 13 There is currently no vaccine for VHF. Infection Control Appropriate isolation precautions for patients with suspected or confirmed VHF include a combination of Airborne, Contact, Droplet and Standard Precautions. Although airborne transmission of these agents appears to be rare, airborne transmission theoretically may occur; therefore, airborne precautions should be instituted for all patients with suspected VHF. Airborne Precautions include the following: • Place the patient in a private room with negative air-pressure ventilation. • Use external air exhaust or high-efficiency particulate air filters if the air is recirculated. • Keep the door to the room closed. Contact Precautions include the following: • Place the patient in a private room if available. • Wear gloves when entering the room, change gloves after having contact with infectious material, remove gloves before leaving the room and wash hands using an antimicrobial agent. Provide the following Personal Protective Equipment (PPE) for healthcare providers: • N-95 respirator or (PAPR) • Double gloves • Impermeable gowns • Face shields • Goggles • Leg and shoe coverings Droplet Precautions include the following: • Place the patient in a private room or in a room with other patients who have the same infection. • When a private room and like infection patients are unavailable, spatial separation of a least three feet should be maintained. • <strong>Healthcare</strong> workers should wear a standard surgical mask when working within three feet of the patient.
Clinical manifestations of VHF 17 VHF Incubation Early Signs/ Symptoms Later Signs/ Symptoms Ebola virus 2-21 days. Fever, severe fatigue headache, myalgias, abdominal pain, diarrhea, may include chest pain, cough, pharyngitis, lymphadenopathy photophobia, conjunctival infection. Marburg virus 2-14 days. Fever, exhaustion, headache, vomiting, conjuncitvitis, enanthem on soft palate, myalgias backache, clouded consciousness. Lassa fever 5-16 days. Gradual development of fever, weakness, malaise. Rift Valley fever 2-6 days. Fever headache, photophobia, and retro-orbital pain. Kyasanur Forest disease Omsk hemorrhagic fever New World aarenaviruses, (Machupo, Junin, Guanarito, Sabia) Standard Precautions include the following: 2-9 days. Sudden onset of fever, myalgias, headache. 2-9 days. Fever, headache, vomiting, enanthem on palate, hyperemia of skin on upper body & mucous membranes. 7-16 days. Gradual onset of fever, sore throat, myalgias, low back pain, abdominal pain. Handwashing Wash hands immediately after gloves are removed, between patient contacts, and when otherwise indicated to avoid transfer of microorganisms to other patients or environments. Gloves Wear gloves when touching blood, body fluid, secretions, excretions, and contaminated items; put on clean gloves just before touching mucous membranes and nonintact skin. Change gloves between tasks and procedures on the same patient after contact with material that may contain a high concentration of microorganisms. Remove gloves promptly after use, before touching noncontaminated items and environmental surfaces, and before going to another patient, and wash hands immediately to avoid transfer of microorganisms to other patients or environments. Maculopapular rash predominantly on trunk, appearing about 5 days after onset of illness, jaundice, and pancreatitis often occur. As disease progresses, bleeding may develop, such as mucous membrane hemorrhages, hematemesis, bloody diarrhea, petechiae, ecchymoses. Maculopapular rash appearing on 5 th to 7 th day on trunk, face, neck, and proximal regions of extremities, nonpruritic. Jaundice and pancreatitis. As disease progresses bleeding develops. Arthralgias, back pain, nonproductive cough by 3 rd day, then severe exudative pharyngitis, maculopapular rash may be seen on fair skinned patients, severe exhaustion by 8 th day. As disease progresses bleeding develops. Hepatitis, bleeding, encephalitis, retinitis. Vomiting and diarrhea. Enanthem with papulovesicular lesions on soft palate. Conjunctival congestion, subconjunctival hemorrhage, mild iritis, retinal and vitreous hemorrhage. cervical and axilary lymphadenopathy, bleeding from nose, gums, GI tract. Sever fever, generalized lymphadenopathy, splenomegaly and pneumonia. Vascular, neurologic manifestations may occur 5-7 days after illness onset, bleeding. Masks, eye protection, face shields Wear a standard surgical mask and eye protection or a face shield to protect mucous membranes of the eyes, nose, and mouth during procedures and activities that are likely to generate splashes or sprays. Place all persons who have had close or high-risk contact with a patient suspected of having VHF during the 21 days following onset of symptoms under medical surveillance. If multiple patients with suspected VHF are admitted to one healthcare facility, group them in the same part of the hospital to minimize exposure to other patients and healthcare workers
Page 1 and 2: Bioterrorism Agents and Barrier Pro
Page 3 and 4: Anthrax Anthrax is caused by the Ba
Page 5 and 6: Clinical Manifestation of Smallpox
Page 7: Clinical manifestations of Botulism
Page 11 and 12: Infection Control Person-to-person
Page 13 and 14: Personal Protective Equipment Perso
Page 15: Ansell Healthcare Europe N.V. River

Download full document (pdf) - Ansell Healthcare Europe

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?